BIOCRATES Life Sciences AG Acquires Metanomics Health GmbH

04-Jan-2018 - Germany

BIOCRATES Life Sciences AG announced the acquisition of Metanomics Health GmbH. Metanomics Health is a metabolomics biomarker development and healthcare services specialist based in Berlin, Germany. At the same time, the company is closing a significant financing round to support future growth. BASF Plant Science GmbH, the former owner of Metanomics Health GmbH, will keep a minority share of BIOCRATES Life Sciences AG. The complementary skills and technologies of the merged companies will enable BIOCRATES to serve the fast-growing metabolomics market as total solution provider, with a focus on healthcare and pharmaceutical applications. The joint company will now culminate years of metabolomics-based discovery in the development, approval and marketing of novel diagnostics, aiming to become the world leader in early disease detection.

“Together, BIOCRATES and Metanomics Health provide the broadest technology and metabolomics product portfolio in the industry. These will enable us to provide deep metabolic phenotyping through targeted metabolomics profiling services, customized assays, targeted screening kits, and comprehensive data interpretation. Moreover, the merger will enable us to develop kits for both Diagnostics and Companion Diagnostics”, said BIOCRATES’ CEO Dr. Wulf Fischer-Knuppertz. “We are looking forward to further developing and expanding our offerings in the life science market. The completed financing round along with the merger allows us to increase our growth through accelerated kit development and regional sales expansion.”

Dr. Tim Bölke, Metanomics Health’s Managing Director, who will continue to lead operations in Berlin and join the management team of BIOCRATES as Chief Medical Officer commented: “Metabolomics has the potential to bring a new dimension to diagnosis and patient stratification in precision medicine as well as to improve the drug discovery and development process. We are looking forward to extending and broadening our services and offerings to improve prognosis and diagnosis in areas of high unmet medical need, ultimately leading to earlier and better treatments.”

BASF Plant Science GmbH, MIG Fonds and GA Asset Fund GmbH & Co. KG (GAF) participated in the financing round.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures